Real World Evaluation of Next-Day Molecular Respiratory Infectious Disease Testing on Healthcare Resource Utilization and Costs

Andrea J French, Maren S Fragala, Azia S Evans, Pallavi Upadhyay, Steven E Goldberg, Jairus Reddy HealthTrackRx, Denton, TX, USACorrespondence: Maren S Fragala, HealthTrackRx, 1500 Interstate 35W, Denton, TX, 76207, USA, Email Maren.Fragala@HealthTrackrx.comPurpose: Advancements in pathogen identifi...

Full description

Saved in:
Bibliographic Details
Main Authors: French AJ, Fragala MS, Evans AS, Upadhyay P, Goldberg SE, Reddy J
Format: Article
Language:English
Published: Dove Medical Press 2025-02-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
Online Access:https://www.dovepress.com/real-world-evaluation-of-next-day-molecular-respiratory-infectious-dis-peer-reviewed-fulltext-article-CEOR
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823857954782183424
author French AJ
Fragala MS
Evans AS
Upadhyay P
Goldberg SE
Reddy J
author_facet French AJ
Fragala MS
Evans AS
Upadhyay P
Goldberg SE
Reddy J
author_sort French AJ
collection DOAJ
description Andrea J French, Maren S Fragala, Azia S Evans, Pallavi Upadhyay, Steven E Goldberg, Jairus Reddy HealthTrackRx, Denton, TX, USACorrespondence: Maren S Fragala, HealthTrackRx, 1500 Interstate 35W, Denton, TX, 76207, USA, Email Maren.Fragala@HealthTrackrx.comPurpose: Advancements in pathogen identification by diagnostic testing may improve patient outcomes. This study evaluated healthcare utilization and costs following diagnostic testing for acute oropharyngeal and respiratory tract infections (RTIs).Patients and Methods: Healthcare utilization and costs were evaluated in patients with acute oropharyngeal infections (n=1,172,693), and RTIs (n=4,005,228) who received a syndromic panel-based PCR test with next-day results (HealthTrackRx, Denton, TX), or no test in the IQVIA PharMetrics® Plus adjudicated claims database.Results: Statistically significant differences were observed between patients who received the PCR test compared to those who received no test. The PCR test cohort had lower total healthcare costs (mean = &dollar;5,601±&dollar;29,170, median = &dollar;807) versus the no test cohort (mean = &dollar;7,460±&dollar;40,817, median = &dollar;1,163) (p = 0.0014) over 6 months, and fewer outpatient visits, other medical service visits, emergency room visits, and inpatient stays (p< 0.0001). Similarly, those who received the PCR test for oropharyngeal infection trended towards lower total healthcare costs (mean = &dollar;4,393±&dollar;13,524, median=&dollar;844) than those who received no test (mean = &dollar;5,503±&dollar;34,141, median = &dollar;956) (p=0.0525) and had fewer outpatient and other medical services (p< 0.0001).Conclusion: Next-day molecular testing for respiratory and oropharyngeal infection lowers healthcare utilization and costs, suggesting improved patient care through reduced need for healthcare resources.Keywords: PCR, NAAT, syndromic multiplex testing, respiratory virus, influenza viruses, respiratory tract infection, pharyngitis, diagnostics, healthcare utilization
format Article
id doaj-art-135a3f593f0a4e8a962145d8fc2cec49
institution Kabale University
issn 1178-6981
language English
publishDate 2025-02-01
publisher Dove Medical Press
record_format Article
series ClinicoEconomics and Outcomes Research
spelling doaj-art-135a3f593f0a4e8a962145d8fc2cec492025-02-11T17:30:56ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812025-02-01Volume 177993100080Real World Evaluation of Next-Day Molecular Respiratory Infectious Disease Testing on Healthcare Resource Utilization and CostsFrench AJFragala MSEvans ASUpadhyay PGoldberg SEReddy JAndrea J French, Maren S Fragala, Azia S Evans, Pallavi Upadhyay, Steven E Goldberg, Jairus Reddy HealthTrackRx, Denton, TX, USACorrespondence: Maren S Fragala, HealthTrackRx, 1500 Interstate 35W, Denton, TX, 76207, USA, Email Maren.Fragala@HealthTrackrx.comPurpose: Advancements in pathogen identification by diagnostic testing may improve patient outcomes. This study evaluated healthcare utilization and costs following diagnostic testing for acute oropharyngeal and respiratory tract infections (RTIs).Patients and Methods: Healthcare utilization and costs were evaluated in patients with acute oropharyngeal infections (n=1,172,693), and RTIs (n=4,005,228) who received a syndromic panel-based PCR test with next-day results (HealthTrackRx, Denton, TX), or no test in the IQVIA PharMetrics® Plus adjudicated claims database.Results: Statistically significant differences were observed between patients who received the PCR test compared to those who received no test. The PCR test cohort had lower total healthcare costs (mean = &dollar;5,601±&dollar;29,170, median = &dollar;807) versus the no test cohort (mean = &dollar;7,460±&dollar;40,817, median = &dollar;1,163) (p = 0.0014) over 6 months, and fewer outpatient visits, other medical service visits, emergency room visits, and inpatient stays (p< 0.0001). Similarly, those who received the PCR test for oropharyngeal infection trended towards lower total healthcare costs (mean = &dollar;4,393±&dollar;13,524, median=&dollar;844) than those who received no test (mean = &dollar;5,503±&dollar;34,141, median = &dollar;956) (p=0.0525) and had fewer outpatient and other medical services (p< 0.0001).Conclusion: Next-day molecular testing for respiratory and oropharyngeal infection lowers healthcare utilization and costs, suggesting improved patient care through reduced need for healthcare resources.Keywords: PCR, NAAT, syndromic multiplex testing, respiratory virus, influenza viruses, respiratory tract infection, pharyngitis, diagnostics, healthcare utilizationhttps://www.dovepress.com/real-world-evaluation-of-next-day-molecular-respiratory-infectious-dis-peer-reviewed-fulltext-article-CEORpcrnaatsyndromic multiplex testingrespiratory virusinfluenza virusesrespiratory tract infectionpharyngitisdiagnosticshealthcare utilization
spellingShingle French AJ
Fragala MS
Evans AS
Upadhyay P
Goldberg SE
Reddy J
Real World Evaluation of Next-Day Molecular Respiratory Infectious Disease Testing on Healthcare Resource Utilization and Costs
ClinicoEconomics and Outcomes Research
pcr
naat
syndromic multiplex testing
respiratory virus
influenza viruses
respiratory tract infection
pharyngitis
diagnostics
healthcare utilization
title Real World Evaluation of Next-Day Molecular Respiratory Infectious Disease Testing on Healthcare Resource Utilization and Costs
title_full Real World Evaluation of Next-Day Molecular Respiratory Infectious Disease Testing on Healthcare Resource Utilization and Costs
title_fullStr Real World Evaluation of Next-Day Molecular Respiratory Infectious Disease Testing on Healthcare Resource Utilization and Costs
title_full_unstemmed Real World Evaluation of Next-Day Molecular Respiratory Infectious Disease Testing on Healthcare Resource Utilization and Costs
title_short Real World Evaluation of Next-Day Molecular Respiratory Infectious Disease Testing on Healthcare Resource Utilization and Costs
title_sort real world evaluation of next day molecular respiratory infectious disease testing on healthcare resource utilization and costs
topic pcr
naat
syndromic multiplex testing
respiratory virus
influenza viruses
respiratory tract infection
pharyngitis
diagnostics
healthcare utilization
url https://www.dovepress.com/real-world-evaluation-of-next-day-molecular-respiratory-infectious-dis-peer-reviewed-fulltext-article-CEOR
work_keys_str_mv AT frenchaj realworldevaluationofnextdaymolecularrespiratoryinfectiousdiseasetestingonhealthcareresourceutilizationandcosts
AT fragalams realworldevaluationofnextdaymolecularrespiratoryinfectiousdiseasetestingonhealthcareresourceutilizationandcosts
AT evansas realworldevaluationofnextdaymolecularrespiratoryinfectiousdiseasetestingonhealthcareresourceutilizationandcosts
AT upadhyayp realworldevaluationofnextdaymolecularrespiratoryinfectiousdiseasetestingonhealthcareresourceutilizationandcosts
AT goldbergse realworldevaluationofnextdaymolecularrespiratoryinfectiousdiseasetestingonhealthcareresourceutilizationandcosts
AT reddyj realworldevaluationofnextdaymolecularrespiratoryinfectiousdiseasetestingonhealthcareresourceutilizationandcosts